Adjunctive use of eptifibatide for complication management during elective neuroendovascular procedures

Travis M Dumont, Peter Kan, Kenneth V. Snyder, L. Nelson Hopkins, Adnan H. Siddiqui, Elad I. Levy

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: A rare complication of neuroendovascular procedures is acute thromboembolism. In the setting of intraprocedural or periprocedural embolism, thrombolytics present a potentially useful therapeutic strategy. A series of patients in whom eptifibatide (a platelet glycoprotein IIb/IIIa receptor inhibitor) was used in the treatment of iatrogenic thromboembolic events occurring during elective neuroendovascular procedures is described. Methods: Consecutive cases between May 2009 and July 2011 in which eptifibatide was administered were identified and individually reviewed for inclusion in this study (n=12). All study patients received a uniform, weight based bolus dose of 180 m g/kg of eptifibatide administered either intra-arterially through the guide catheter or intravenously. Eptifibatide infusion (2 μg/kg/min) for 24 h after bolus dose administration was continued at the discretion of the surgeon. Procedural details are described and illustrative cases presented. Results: Three major categories of thromboembolic events were isolated in the course of review of study cases: acute focal neurological decline and no radiographic findings of flow limitation (eight patients), radiographic findings with or without symptoms (two patients) and persistent particulate debris during flow reversal as part of a carotid revascularization procedure (two patients). Following eptifibatide administration, no patient experienced hemorrhagic complications, and neurologic improvement to baseline level was noted in 10 of 12 patients. Conclusion: Eptifibatide may be an effective therapeutic strategy in the event of thromboembolism during elective neuroendovascular procedures.

Original languageEnglish (US)
Pages (from-to)226-230
Number of pages5
JournalJournal of NeuroInterventional Surgery
Volume5
Issue number3
DOIs
StatePublished - May 2013
Externally publishedYes

Fingerprint

Thromboembolism
Integrin beta3
Platelet Glycoprotein GPIIb-IIIa Complex
eptifibatide
Embolism
Nervous System
Therapeutics
Catheters
Weights and Measures
Surgeons

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

Adjunctive use of eptifibatide for complication management during elective neuroendovascular procedures. / Dumont, Travis M; Kan, Peter; Snyder, Kenneth V.; Hopkins, L. Nelson; Siddiqui, Adnan H.; Levy, Elad I.

In: Journal of NeuroInterventional Surgery, Vol. 5, No. 3, 05.2013, p. 226-230.

Research output: Contribution to journalArticle

Dumont, Travis M ; Kan, Peter ; Snyder, Kenneth V. ; Hopkins, L. Nelson ; Siddiqui, Adnan H. ; Levy, Elad I. / Adjunctive use of eptifibatide for complication management during elective neuroendovascular procedures. In: Journal of NeuroInterventional Surgery. 2013 ; Vol. 5, No. 3. pp. 226-230.
@article{ff4db201cf5b44c885cd22a004384203,
title = "Adjunctive use of eptifibatide for complication management during elective neuroendovascular procedures",
abstract = "Objective: A rare complication of neuroendovascular procedures is acute thromboembolism. In the setting of intraprocedural or periprocedural embolism, thrombolytics present a potentially useful therapeutic strategy. A series of patients in whom eptifibatide (a platelet glycoprotein IIb/IIIa receptor inhibitor) was used in the treatment of iatrogenic thromboembolic events occurring during elective neuroendovascular procedures is described. Methods: Consecutive cases between May 2009 and July 2011 in which eptifibatide was administered were identified and individually reviewed for inclusion in this study (n=12). All study patients received a uniform, weight based bolus dose of 180 m g/kg of eptifibatide administered either intra-arterially through the guide catheter or intravenously. Eptifibatide infusion (2 μg/kg/min) for 24 h after bolus dose administration was continued at the discretion of the surgeon. Procedural details are described and illustrative cases presented. Results: Three major categories of thromboembolic events were isolated in the course of review of study cases: acute focal neurological decline and no radiographic findings of flow limitation (eight patients), radiographic findings with or without symptoms (two patients) and persistent particulate debris during flow reversal as part of a carotid revascularization procedure (two patients). Following eptifibatide administration, no patient experienced hemorrhagic complications, and neurologic improvement to baseline level was noted in 10 of 12 patients. Conclusion: Eptifibatide may be an effective therapeutic strategy in the event of thromboembolism during elective neuroendovascular procedures.",
author = "Dumont, {Travis M} and Peter Kan and Snyder, {Kenneth V.} and Hopkins, {L. Nelson} and Siddiqui, {Adnan H.} and Levy, {Elad I.}",
year = "2013",
month = "5",
doi = "10.1136/neurintsurg-2012-010271",
language = "English (US)",
volume = "5",
pages = "226--230",
journal = "Journal of NeuroInterventional Surgery",
issn = "1759-8478",
publisher = "BMJ Publishing Group",
number = "3",

}

TY - JOUR

T1 - Adjunctive use of eptifibatide for complication management during elective neuroendovascular procedures

AU - Dumont, Travis M

AU - Kan, Peter

AU - Snyder, Kenneth V.

AU - Hopkins, L. Nelson

AU - Siddiqui, Adnan H.

AU - Levy, Elad I.

PY - 2013/5

Y1 - 2013/5

N2 - Objective: A rare complication of neuroendovascular procedures is acute thromboembolism. In the setting of intraprocedural or periprocedural embolism, thrombolytics present a potentially useful therapeutic strategy. A series of patients in whom eptifibatide (a platelet glycoprotein IIb/IIIa receptor inhibitor) was used in the treatment of iatrogenic thromboembolic events occurring during elective neuroendovascular procedures is described. Methods: Consecutive cases between May 2009 and July 2011 in which eptifibatide was administered were identified and individually reviewed for inclusion in this study (n=12). All study patients received a uniform, weight based bolus dose of 180 m g/kg of eptifibatide administered either intra-arterially through the guide catheter or intravenously. Eptifibatide infusion (2 μg/kg/min) for 24 h after bolus dose administration was continued at the discretion of the surgeon. Procedural details are described and illustrative cases presented. Results: Three major categories of thromboembolic events were isolated in the course of review of study cases: acute focal neurological decline and no radiographic findings of flow limitation (eight patients), radiographic findings with or without symptoms (two patients) and persistent particulate debris during flow reversal as part of a carotid revascularization procedure (two patients). Following eptifibatide administration, no patient experienced hemorrhagic complications, and neurologic improvement to baseline level was noted in 10 of 12 patients. Conclusion: Eptifibatide may be an effective therapeutic strategy in the event of thromboembolism during elective neuroendovascular procedures.

AB - Objective: A rare complication of neuroendovascular procedures is acute thromboembolism. In the setting of intraprocedural or periprocedural embolism, thrombolytics present a potentially useful therapeutic strategy. A series of patients in whom eptifibatide (a platelet glycoprotein IIb/IIIa receptor inhibitor) was used in the treatment of iatrogenic thromboembolic events occurring during elective neuroendovascular procedures is described. Methods: Consecutive cases between May 2009 and July 2011 in which eptifibatide was administered were identified and individually reviewed for inclusion in this study (n=12). All study patients received a uniform, weight based bolus dose of 180 m g/kg of eptifibatide administered either intra-arterially through the guide catheter or intravenously. Eptifibatide infusion (2 μg/kg/min) for 24 h after bolus dose administration was continued at the discretion of the surgeon. Procedural details are described and illustrative cases presented. Results: Three major categories of thromboembolic events were isolated in the course of review of study cases: acute focal neurological decline and no radiographic findings of flow limitation (eight patients), radiographic findings with or without symptoms (two patients) and persistent particulate debris during flow reversal as part of a carotid revascularization procedure (two patients). Following eptifibatide administration, no patient experienced hemorrhagic complications, and neurologic improvement to baseline level was noted in 10 of 12 patients. Conclusion: Eptifibatide may be an effective therapeutic strategy in the event of thromboembolism during elective neuroendovascular procedures.

UR - http://www.scopus.com/inward/record.url?scp=84878401163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878401163&partnerID=8YFLogxK

U2 - 10.1136/neurintsurg-2012-010271

DO - 10.1136/neurintsurg-2012-010271

M3 - Article

C2 - 22411930

AN - SCOPUS:84878401163

VL - 5

SP - 226

EP - 230

JO - Journal of NeuroInterventional Surgery

JF - Journal of NeuroInterventional Surgery

SN - 1759-8478

IS - 3

ER -